Health committee  There are two things, and I think Phil touched on this. Peer review is very important for scientific journals, and when you're talking about medicine and therapeutics, peer review, when it comes to economic analysis, is more around research methodology, but they don't really typi

Health committee  No, the number hasn't changed much. We are between 9,500 and 9,800 storefronts. There is some shifting, some closing of smaller locations and consolidation into bigger enterprises, but there hasn't been a plethora of....

Health committee  It may or may not. It's possible.

Health committee  No.

Health committee  No, it was not.

Health committee  Can I answer that?

Health committee  Sure. I think you're reading something that was probably written six months or so ago, when up to that point no other models had really been under serious consideration nationally. The ones we put forward in our paper would be the Quebec model, which was discussed earlier today,

Health committee  It's not a matter of what I think. It was the consultant who is the expert in the field who thought that was the appropriate price, and we have no reason to question it.

Health committee  Yes.

Health committee  That wasn't for pharmacists' services. There's a separate conversation around pharmacists' services, which I alluded to. They have not been costed. That's the medication management and the medication adherence.

Health committee  You don't have to. We highly recommend that you do. There's not much point in having a national pharmacare program if you're not ensuring that people are using medications appropriately.

Health committee  Of course. Yes, we did.

Health committee  That was the researcher's perspective.

Health committee  Absolutely. We were, again, just putting the facts on the table. Mechanically, that's a transfer of costs of $6.6 billion. How the government manages to offset that, or partially offset it, is completely up to the managers.

Health committee  It doesn't have to. Again, we're not for or against a fully public-paid program. We wanted to put some facts on the table. Any national pharmacare program can work effectively as long as it has the patient's interest in mind, ultimately, and not just cost savings.